Price
CHART BY
Frequently asked questions
What is BIOAGE's market capitalization?
The market capitalization of BIOAGE is €431.85M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BIOAGE?
BIOAGE's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -€1.815. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BIOAGE's stock?
Currently, 4 analysts cover BIOAGE's stock, with a consensus target price of €10.30. Analyst ratings provide insights into the stock's expected performance.
What is BIOAGE's revenue over the trailing twelve months?
Over the trailing twelve months, BIOAGE reported a revenue of €5.08M.
What is the EBITDA for BIOAGE?
BIOAGE's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -€76.86M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BIOAGE?
BIOAGE has a free cash flow of -€50.78M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BIOAGE have, and what sector and industry does it belong to?
BIOAGE employs approximately 64 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BIOAGE's shares?
The free float of BIOAGE is 22.51M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- €431.85M
- EPS (TTM)
- -€1.815
- Free Float
- 22.51M
- Revenue (TTM)
- €5.08M
- EBITDA (TTM)
- -€76.86M
- Free Cashflow (TTM)
- -€50.78M
Pricing
- 1D span
- €14.35€18.15
- 52W span
- €2.63€15.39
Analyst Ratings
The price target is €10.30 and the stock is covered by 4 analysts.
Buy
1
Hold
3
Sell
0
Information
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
- Employees
- 64
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BIOA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet